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The Etiology and Treatment
of Nicotine Dependence
A Biopsychosocial Perspective

hronic use of tobacco-containing
products, particularly cigarettes,
remains one of the most avoidable
causes of death and illness in the United States
and claims the lives of more than 430,000 individuals each year (U.S. Department of Health
and Human Services [DHHS], 1999). The
number of tobacco-related deaths alone
exceeds that of deaths due to AIDS, murders,
other drugs, alcohol, car crashes, fires, and suicides combined (Centers for Disease Control
and Prevention [CDC], 2002). Illnesses associated with tobacco use include, but are not
limited to, laryngeal cancer, oral cancer,
esophageal cancer, obstructive pulmonary disease, cardiovascular disease, intrauterine
growth retardation, and low birth weight
(DHHS, 1999). Evidence of significant health
risks due to environmental tobacco smoke has
also been documented. Adverse health risks
caused by exposure to "secondhand" tobacco

smoke include lung cancer, asthma, respiratory
infections, and decreased pulmonary function
(DHHS, 1999).Despite public health efforts to
reduce tobacco use in the United States, adult
prevalence rates have not changed significantly, and in some cases increases were
observed during the 1990s (CDC, 2002). For
example, the overall rate of adult cigarette
smokers has decreased slightly from 25.0% to
23.3% across all age groups except that of 18to 24-year-olds (CDC, 2002), whereas the use
of smokeless (spit) tobacco and cigars has
increased substantially (U.S. Department of
Agriculture, 1997). To date, 65.5 million
Americans continue to use tobacco products
on a regular basis (CDC, 2002) and appear to
be more difficult to treat than their counterparts of the 1970s and 1980s (Irvin &
Brandon, 2000). As such, tobacco use continues to represent an important health behavior
that faces health care professionals.

102

BEHAVIORS THAT COMPROMISE HEALTH

DEFINITIONS AND DESCRIPTION
OF NICOTINE DEPENDENCE
The addictive process associated with tobacco
use has been studied primarily with cigarette
smoking, but there is a growing body of literature examining this process in spit tobacco (e.g.,
Hatsukami & Severson, 1999; McChargue &
Collins, 1998) and cigar use (e.g., Henningfield,
Fant, Radzius, & Frost, 1999). The DSM-IVTR (Diagnostic and Statistical Manual of
Mental Disorders, fourth edition, text revision
[American Psychiatric Association, 20001)
classifies chronic tobacco use as a significant
clinical impairment because of the psychological and neurobiological effects caused by
nicotine-the presumed addictive ingredient
found in tobacco products (Henningfield &
Heishman, 1995; Robinson & Pritchard,
1992). As a clinical disorder, chronic tobacco
use is classified as nicotine dependence when
three of seven criteria are met within the same
12-month period. In particular, the four most
prominent criteria of nicotine dependence are
(a)developing a tolerance to nicotine, (b)experiencing nicotine withdrawal, (c)showing a
persistent desire or unsuccessful efforts to quit
or cut down the use of nicotine, and (d)continuing to use nicotine despite the development of
physical or psychological problems that are
likely to have been caused or exacerbated by
tobacco products (American Psychiatric
Association, 2000). Other general criteria for
nicotine dependence include using larger
amounts over a longer period of time; spending
a great deal of time in activities necessary to
obtain, use, or recover from nicotine; and experiencing impaired functioning (American
Psychiatric Association, 2000).

Tolerance
Simply stated, tolerance is viewed as a
diminished response or an adaptation to a
given dose after repeated use (Balfour, 1991;
Benowitz, 1990). Subjective, behavioral, and

physiological adaptation has been shown
following repeated exposure to nicotine
(Balfour, 1991). For example, dizziness, nausea, and vomiting are associated with initial
exposure to cigarette smoking; however,
these symptoms disappear rapidly following
habitual exposure (Benowitz, 1990). For the
most part, tolerance to nicotine develops
quickly, sometimes within 35 minutes of
administration (Porchet,Benowitz, & Sheiner,
1988). Once tolerance is developed, certain
effects (e.g., dizziness) are more transient and
dissipate rapidly following a short period of
abstinence (Benowitz, 1990), whereas tolerance to most of the subjective and behavioral
effects appears to be more long term (Perkins
et al., 2001). Researchers have suggested that
the rapid "re-sensitization" of the more transient effects, such as the "rush" one experiences from the first cigarette of the day, may
partially explain why tobacco users tend to
show stable use patterns without progressively
increasing their dose amounts over time
(Benowitz, 1990).

Nicotine Withdrawal
Nicotine withdrawal is defined as the manifestation of behavioral, subjective, physiological, and biochemical changes that occur when
a person abruptly cuts down or quits using
nicotine-containing products (Hughes, Higgins,
& Hatsukami, 1990). The withdrawal syndrome includes four or more of the following
symptoms: (a)dysphoric or depressed mood;
(b)insomnia; (c)irritability, frustration, or
anger; (d)anxiety; (e)difficulty in concentrating; (f) restlessness; (g) decreased heart rate;
and (h) increased appetite or weight gain
(American Psychiatric Association, 2000). In
addition, these symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of
functioning, and the symptoms are not better
accounted for by another mental disorder
(AmericanPsychiatric Association, 2000).
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Declining blood levels of nicotine have been
associated with the onset of nicotine withdrawal; however, it is not clear whether the
duration and severity of these symptoms are
entirely attributable to the rate at which nicotine dissipates from a person's system. For
example, nicotine reaches the brain within 10
to 19 seconds after smoking a cigarette, with
brain levels of nicotine declining rapidly over
20 to 30 minutes (Benowitz, 1990). On the
other hand, nicotine levels in the brain from spit
tobacco tend to increase gradually, reaching
their peak about 30 minutes after administration, and decline slowly over 2 hours or more
(Benowitz, Porchet, & Jacob, 1990). Despite
the differing rates of nicotine absorption and
depletion observed across these two modes of
administration, spit tobacco users consistently
report similar experiences of withdrawal,
both in terms of the types of symptoms experienced (Hatsukami, Gust, & Keenan, 1987;
McChargue & Collins, 1998; McChargue,
Collins, & Cohen, 2002) and in terms of the
level of severity (McChargue & Collins, 1998).
Thus, the severity of withdrawal symptoms
may be dictated by a variety of individual differences, including tobacco use patterns (Killen,
Fortmann, Newman, & Varady, 1991), psychiatric comorbidities (Pomerleau, Marks, &
Pomerleau, 2000), and personality factors
(Gilbert& Gilbert, 1995; Madden et al., 1997).
In general, nicotine withdrawal occurs within
24 hours of abruptly reducing or quitting nicotine use, peaks between 48 hours (Hughes &
Hatsukami, 1986)and 2 weeks (Shlffman,Paty,
Guys, Kassel, & Elash, 1995; West, Hajek, &
Belcher, 1989), and resolves after 1 month of
abstinence (Hughes, 1992). However, similar
to withdrawal severity, the duration of withdrawal patterns are also variable. For example,
increases in hunger and weight gain are the most
persistent symptoms, lasting as long as 6 months
to 1 year (Hughes, 1992; Klesges et al., 1997).
In addition, individuals who quit using nicotinecontaining products do not always report
increased anxiety; however, in cases where
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anxiety is reported, it could be a function of
brief lapses in their abstinence (e.g., periodically
smoking one cigarette and then resuming abstinence west & Hajek, 1997). Finally, depressive symptoms may persist beyond 1 month,
especially among people who have experienced
a major depressive episode in the past (Borrelli
et al., 1996).In fact, data suggest that there is at
least a 33% chance that people with a hstory of
major depression will experience clinically siglllficant levels of depressive symptoms at any
time across the first 12 months of nicotine abstinence (Borrelli et al., 1996; Tsoh et al., 2000).

Other Prominent Criteria
for Nicotine Dependence

,

Individuals who use nicotine-containing
products also show signs and symptoms associated with the remaining criteria for nicotine
dependence. Specifically, a strong and persistent desire to use tobacco maintains use
patterns (Baker, Morse, & Sherman, 1986;
Tiffany, 1990) and contributes to difficulties in
quitting (e.g., Tracy, 1994). Researchers question whether nicotine's ability to alter emotions (Baker et al., 1986; Carmody, 1990; Hall,
Munoz, Reus, & Sees, 1993)drives the motivation to use tobacco products or whether this
increased motivation is more automatic
(Tiffany, 1990) and independent from emotion
(Robinson & Berridge, 2000). Nevertheless,
nicotine administration appears to create an
intense motivation to use tobacco products that
is difficult to break regardless of the mechanism
that promotes the powerful desire to continue
tobacco use.
Individuals who use tobacco also tend to
experience extreme difficulty in quitting, and
unsuccessful efforts usually are made before
they are able to quit permanently. In fact, less
than 5% of individuals who meet criteria
for nicotine dependence are able to quit on
their own (Fiore et al., 1990). This percentage
increases to as high as 30% with assisted
treatment for nicotine dependence (Fiore et al.,
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2000). As stated earlier, fewer and fewer
people have quit using tobacco products over
the past decade (CDC, 2002) as compared
with previous decades (Emrnons, Kawachi, &
Barclay, 1997). The apparent plateau of
cigarette smoking rates and the increase of spit
tobacco and cigar use may suggest that today's
tobacco users are more resistant to treatment
efforts and may even possess underlying vulnerabilities that further establish tobacco use
patterns (Gilbert & Gilbert, 1995).
Finally, it is not uncommon for nicotinedependent individuals to continue to use
tobacco products despite physical or psychological problems that may result from chronic
nicotine exposure. Familiar examples include
the patient with emphysema who continues
to smoke while attached to an oxygen tank
despite the inherent danger of doing so and
the patient who smokes through a tracheotomy tube. Overall, there is anecdotal
and empirical evidence suggesting that many
patients with cardiovascular disease, chronic
obstructive pulmonary disease, and/or cancerall of which are related to chronic tobacco use
(DHHS, 1999)--continue their patterns of
use (Gritz, Kristeller, & Burns, 1993).
Moreover, continued use is associated with a
heightened mortality rate, whereas cessation
post-disease diagnosis may improve prognoses (Gritz et al., 1993).

A BIOPSYCHOSOCIAL
LEARNING MODEL OF
NICOTINE DEPENDENCE
Nicotine dependence is a complex biopsychosocial phenomenon that originates from
learning theory. The most parsimonious explanation is that nicotine's effects on neurobiological substrates interact with behavioral,
emotional, and cognitive domains to create
dependence. Evidence also suggests that
chronic use patterns may produce secondary
conditioning of the pharmacological effects on

the brain (Rose & Levin, 1991)and sensitization
of some neurobiological systems (Robinson &
Berridge, 2000; Watkins, Koob, & Markou,
2000). In general, tobacco use behaviors are
maintained by nicotine's ability to enhance
desirable effects (positive reinforcement) and to
dispel undesirable effects (negative reinforcement). Over time, frequent and repeated use of
tobacco products in specific situations, environments, and emotional states may automatically
trigger tobacco use (secondary conditioning
and sensitization) (Rose & Levin, 1991;
Shiffrnan, 1991). For example, a person who
typically smokes while talking on the phone
may light another cigarette when the phone
rings without realizing that he or she already
had a cigarette lit.

Positive Reinforcement
and Sensitization: A Stoy
of Rewarding Properties
The most widely studied neurobiological
substrate associated with nicotine-related
positive reinforcement is dopamine (Wise,
1998). The mesolimbic dopamine system has
long been touted as the reward center of the
brain that shapes goal-directed behavior
(Olds & Milner, 1954; Stein, Belluzzi,
Ritter, & Wise, 1974), including drug use
behavior (Di Chiara, 1998; Koob & Le
Moal, 1997). Consistent with the reward
hypothesis of dopamine, nicotine's preferential binding to nicotinic cholinergic receptors
within the mesolimbic dopamine system
(Clarke & Pert, 1985) and nicotine's reliable
activation of dopamine release within the
same system (Pomerleau & Pomerleau, 1984)
suggest that nicotine produces powerful
rewarding effects for people who use tobacco.
The rewarding effects of nicotine become
more powerful over time due to the biphasic
nature of nicotine's influence on dopamine
release. During nicotine administration, the
dopaminergic system becomes sensitized
rather than habituated (e.g., tolerance)
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(Robinson & Berridge, 2000; Watkins et al.,
2000). In other words, dopamine release is
enhanced, rather than diminished, from
repeated exposure to nicotine. As levels of
nicotine are depleted during abstinence,
dopamine also shows neuroadaptative effects.
Neuroadaptation reflects the progressive
blunting of naturally occurring dopamine
(Epping-Jordan, Watkins, Koob, & Markou,
1998). The ever-growing disparity between
sensitized dopamine release from nicotine
administration and blunted naturally occurring dopamine release during nicotine abstinence is hypothesized to alter reward
thresholds (Watkins et al., 2000), presumably
making it very difficult for tobacco users
to experience pleasure without the aid of
nicotine.
Glutamate functioning also appears to play
an important role in the positive reinforcement
of nicotine via its symbiotic relationship with
dopamine. As discussed earlier, dopaminergic
functioning is regarded as the primary mechanism that accounts for the rewarding properties
of nicotine. However, glutamate may actually
strengthen nicotine's rewarding properties and
permanently implant the effect of such reward
into long-term memory. For instance, nicotine
administration has been shown to increase glutamate release within the mesolimbic dopamine
system (Garcia-Munoz, Patino, Young, &
Groves, 1996) as well as within hippocampal
neurons associated with memory and learning
(Radcliffe, Fisher, Gray, & Dani, 1999). Given
that glutamate is strongly linked to learning and
memory (Goda & Stevens, 1996), it has been
hypothesized that the simultaneous activation
of the hippocampal and dopaminergic systems
solidifies the rewarding properties of nicotine
(Mansvelder & McGehee, 2000). Even after
long periods of abstinence, the responsiveness
of these systems to nicotine remains abnormal,
suggesting that these neurotransmitters play a
substantial role in the long-lasting, enduring
changes associated with nicotine dependence
(Pulvirenti & Diana, 2001).

1

These long-lasting memories may help to
explain the incongruent psychosocial findmgs
related to the reward obtained from nicotine
administration. A standard assumption has
been that self-reported pleasure (e.g., positive
affect or euphoria) acts as a substitute for the
rewarding effects of nicotine. However, empirical evidence has not consistently produced data
to support ths assumption. If self-reportedpleasure mimicked the neurobiological substrates,
one would expect that pleasure would show
sensitizing effects (i.e., more and more pleasure
from repeated exposure) after nicotine adrmnistration and would show acute decreases in
pleasure during nicotine abstinence. Although
research shows the expected decrease in pleasure following nicotine abstinence (Hughes&
Hatsukami, 1986),euphoric effects during nicotine administration are minimal (Pomerleau &
Pomerleau, 1992) and may further dmmish,
rather than increase, with repeated exposure
(Robinson& Berridge, 2000). If pleasure diminishes with chronic nicotine use and is not llnked
with doparnine sensitization, memories about
the pleasure-enhancing effects of nicotine may
be sufficient for continued motivation to selfa b s t e r nicotine.
As noted earlier, the rewarding effects of
nicotine are long-lasting in a tobacco user's
memory system. A plausible psychosocial
mechanism that takes into account these
embedded reward effects is positive smoking
expectancies or the belief that smoking will
lead to a positive outcome (e.g., relaxation).
For decades, positive drug expectancies have
been shown to reflect long-term drug use patterns (Vuchinich & Tucker, 1988). In fact, a
recent study showed that smoking outcome
expectancies combine with one's tendency
to experience negative affective states to
predict smoking behavior over time (Cohen,
McCarthy, Brown, & Myers, 2002). These
findings indicate that at least part of the
commonly observed relationship between
negative affect and smoking behavior can be
explained by smoking expectancies.
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Negative Reinforcement:
A Story of Emotion Regulation
When considering negative reinforcement
associated with tobacco use disorders, nicotine
administration is believed to have negative
mood-alleviating properties via its manipulation of neurotransmitters such as serotonin
car mod^, 1990; Hall et al., 1993). Specifically, low levels of serotonin have been strongly
associated with negative mood states (Maes &
Meltzer, 1995), and nicotine administration
appears to increase levels of this neurotransmitter (Kenny, File, & Neal, 2000). In fact,
nicotine's ability to elevate serotonin levels
may partially explain why people report that
using nicotine-containing products alleviates
negative affective states car mod^, 1990; Hall
et al., 1993). Consistent with the serotonin
hypothesis of nicotine dependence, when one
abstains from nicotine, medications that
improve the efficiency of serotonin (e.g., serotonin reuptake inh~bitorssuch as fluoxetine)
prolong short-term abstinence (Niaura et al.,
2002), particularly among smokers with high
baseline levels of depression (Hitsman et al.,
1999). Moreover, once people abstaining from
nicotine are taken off of this type of medication,
there is an increased likelihood that they will
experience a major depressive episode (e.g.,
Borrelli et al., 1996). Hence, this depressive vulnerability during nicotine abstinence is particularly salient for depression-prone individuals.
Although many people report using tobacco
products due to their negative mood-alleviating
properties (Spielberger, Foreyt, Reheiser, &
Poston, 1998),psychosocial research investigating this hypothesis is mixed. It is clear that after
short-term abstinence, nicotine administration
will reverse any negative affective symptoms
associated with the nicotine withdrawal syndrome. However, it remains unclear whether
nicotine has the same effect on negative affect
that is not associated with nicotine withdrawal.
In some studies, administrationof nicotine exhibits the expected mood-alleviating properties.

Specifically, older heavy smokers show dosedependent relief from stress and anxiety
following nicotine administration (Gilbert,
Robinson, Chamberlin, & Spielberger, 1989),
with higher doses of nicotine producing the
greatest mood relief (Gilbert et al., 1989;
Perkins et al., 1993). In addition, nicotine
replacement therapy produces clinically significant reductions in symptoms of depression
among nonsmokers suffering from major
depression (Salin-Pascual, Rosas, JimenezGenchi, & Rivera-Meza, 1996). Nevertheless,
mood responses that are not shown to be
related to nicotine withdrawal are highly
variable. For instance, some evidence actually
indicates that nicotine creates higher levels of
anxiety and stress (Parrott, 1999; Piasecki &
Baker, 2000). Similarly, smoking in response to
depression may increase, rather than decrease,
symptoms of depression among smokers with
a ruminative coping style (Richmond, Spring,
Sornmerfeld, & McChargue, 2001).
Despite the apparent inconsistencies shown
among studies examining negative mood relief
from nicotine administration, the importance
of the negative reinforcing properties of nicotine should not be minimized. In fact, if only a
fraction of individuals achieve negative mood
relief from the administration of nicotine, negative affect's role in the maintenance of tobacco
use behaviors remains quite salient. For
example, both baseline and post-quit negative
affect predict relapse (Pomerleau, Adkins, &
Pertschuk, 1978; Swan, Ward, & Jack, 1996;
West et al., 1989).Furthermore, a large portion
of tobacco users suffer from psychological
problems that are associated with affective dysregulation (Breslau, 1995). Finally, personality
traits that increase the likelihood of experiencing frequent and persistent bouts of negative
affect predict tobacco use behaviors and relapse
(Gilbert & Gilbert, 1995).Although it remains
unclear as to the properties of nicotine that negatively reinforce tobacco use, there is sufficient
evidence to implicate the importance of negative reinforcement in nicotine dependence.
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Classical Conditioning:
A Sto y of Automatic Processes
Classical conditioning occurs when nicotine administration (unconditioned stimulus)
produces psychological and physiological
states (unconditioned response) that are
repeatedly paired with neutral stimuli (conditioned stimulus).In other words, chronic nicotine administration elicits many reinforcing
properties that eventually become conditioned
to environmental and psychological stimuli
(Iwamoto, Fudala, Mundy, & Williamson,
1987; Rose & Levin, 1991). Over time, the
repeated pairings between the once neutral
stimuli and nicotine administration produce
conditioned responses that initiate and maintain tobacco use behavior (Rose & Levin,
1991). Conditioned responses from emotional
and environmental cues reflect the activation
of cognitive (Tiffany, 1990),emotional (Baker
et al., 1986), and physiological (Robinson &
Berridge, 2000) domains. Exposure to such
cues evokes strong tobacco use motivation or
urges. Some researchers hypothesize that
this increase in motivation reflects the desire
to evoke a pleasant feeling or to take away
unpleasant states (Baker et al., 1986), whereas
others view this increased motivation as more
automatic (Tiffany, 1990), that is, driven by
sensitized neurobiological systems (Robinson
& Berridge, 2000).

OTHER IMPORTANT
FACTORS IN NICOTINE
DEPENDENCE RESEARCH

Genetics
The development of nicotine dependence
cannot result entirely from random interactions between neurobiological and psychosocial factors. It has been suggested that
individuals who use tobacco and become nicotine dependent may be different from individuals who do not use tobacco because of

1

biologically based predispositionsthat produce
qualitatively different reinforcement from
nicotine administration (Pomerleau & Kardia,
1999). Evidence supporting the notion that
genetic factors dictate who is likely to become
nicotine dependent comes from a variety of
sources. For example, twin studies have shown
greater concordance rates in monozygotic
twins than in dizygotic twins, with heritability
estimates of 53% for tobacco use (see review
by Hughes, 1986).In addition, certain individuals may be more sensitive to nicotinic properties than are others. A selective sensitivity to
nicotine is hypothesized to produce more rapid
tolerance and more extensive self-administration patterns (Pomerleau, 1995). As such,
genetic factors may help to explain why certain
subgroups of smokers become more dependent
at earlier ages (e.g., Madden et al., 1999) and
have extreme difficulties in quitting (e.g.,
Lerman et al., 1999).

Gender and Ethnicity
Rates of nicotine dependence appear to differ across gender and ethnic groups. In addition, the proportions of men and women who
use tobacco products vary greatly in some
countries, such as Japan and Greece, but not in
others, such as the United States and the United
Kingdom (Grunberg, Winders, & Wewers,
1991). Thus, it may be that tobacco use is reinforced differently for women in countries where
as many women use tobacco products as do
men. In addition, certain minority populations
(e.g., Afr~can Americans) within the United
States report higher rates of tobacco use than
do Caucasians (CDC, 1999), and women and
minorities appear to be less successful at quitting (Piper, Fox, Welsch, Fiore, & Baker,
2001). Therefore, these individuals are at
greater risk for contracting smoking-related illnesses, making it very important to consider
how gender and ethnicity influence the recruitment, retention, and treatment of nicotinedependent individuals (Piper et al., 2001).
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More is known about the etiology and
treatment of nicotine dependence for women
than for different ethnic groups. The scarcity of
research on minorities that use tobacco products
has led many researchers and practitioners to
examine nicotine dependence among minority
populations. Contemporary knowledge regarding what motivates U.S. women to use tobacco
products, pamcularly cigarettes, has focused on
two primary issues: (a)affect regulation and
(b)weight control. In general, women are more
affectively vulnerable than men, and it is
believed that ths vulnerability is well suited for
nicotine's mood-alleviating effects. As such,
women may receive greater mood regulatory
benefits from smokmg than do men, and this is
believed to partially explain why women have
more difficulty in quitting (Piperet al., 2001). In
addition, women frequently express concern
about gaining weight after they quit smoking
(Klesges & Klesges, 1988). This concern is not
surprising given that individuals who are abstinent for 1 year will gain an average of 13
pounds (Klesges et al., 1997).

Comorbid Personality
and Psychopathology
The influence of personality on tobacco use
is based on the belief that traits predispose
people to frequent and persistent aversive
mood states (Cloninger, 1987; Tellegen, 1985;
Tornkins & McCarter, 1964). As such, many
theorize that chronic exposure to mood dysregulation ~rovidesample opportunity for people to
learn that tobacco products are an efficient
source of relief from these problematic affective
states. Traits that are associated with compromised affective systems and tobacco use behavior include sensation seeking, neuroticism,
extroversion, and psychoticism (Gilbert &
Gilbert, 1995; Spielberger &Jacobs, 1982).
Contemporary research has identified an
overwhelming proportion of patients with psychiatric mood, anxiety, and psychotic problems as possessing high levels of comorbid

nicotine dependence (Hughes, Hatsukami,
Mitchell, & Dahlgren, 1986). Comorbid psychopathology represents an important issue
to address in nicotine dependence research
because these individuals report excessive
dependence levels and have extreme difficulty
in quitting (Hughes et al., 1986; McChargue,
Gulliver, & Hitsman, 2002a, 2002b). Moreover, psychiatric smokers are at a heightened
risk of smoking and psychiatric-related health
problems as compared with nonsmoking psychiatric patients and nonpsychiatric smokers
(Jeste, Gladsjo, Lindamer, & Lacro, 1996;
Linkins & Cornstock, 1990). Prevalence rates
of smoking among this population range from
31% to 90%, depending on the psychiatric
disorder (Beckham et al., 1997; de Leon et al.,
1995; Hughes eta]., 1986).
It has been hypothesized that chronic
tobacco use observed among individuals with
psychopathological problems reflects selfmedicating behaviors. According to the selfmedication hypothesis, psychiatric patients
smoke in part because nicotine helps to regulate their symptomatology (Gilbert & Gilbert,
1995). For example, patients with major
depression may smoke to improve depressed
mood states (Hall et al., 1993). Similarly,
patients with schizophrenia may find that
smoking helps to reduce negative symptoms
such as anhedonia, apathy, blunted affect, and
emotional withdrawal (McChargue et al.,
2002a, 2002b). Finally, patients with posttraumatic stress disorder and other anxiety disorders may smoke to cope with emotional and
physiological distress (Beckham et al., 1997).
This self-medication process transforms
tobacco use into an extremely rewarding
behavior for psychiatric individuals as compared with nonpsychiatric cohorts who
report similar tobacco use patterns (Spring,
Pingitore, & McChargue, in press). As such,
the goal of complete abstinence might not
be initially possible for some psychiatric
subgroups (e.g., individuals diagnosed with
schizophrenia).These individuals may require
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a stepped care approach that focuses on
reducing exposure to tobacco toxins until the
individuals are able to stabilize lower rates of
tobacco use and learn adequate coping skills
(McChargue et al., 2002a, 2002b).

ASSESSMENT AND TREATMENT
As discussed earlier, nicotine dependence is
maintained by many factors across diverse
patient populations. Another issue that leads
to difficulties in the treatment and assessment
of nicotine dependence is the pervasive nature of
tobacco use. Specifically, the widespread use of
tobacco products forces clinical health psychologists to address issues related to this construct
in a variety of settings and situations. Hence,
clinicians are encouraged to be mindful of the
settings or situations in which they deliver their
interventions (Collins et al., 1999). Overall,
it is recommended that a multidisciplinary
approach to the assessment and treatment of
nicotine dependence be used if long-term abstinence is to be achieved (Fagerstrom, 1991).

Assessment of Nicotine Dependence
The assessment of nicotine dependence
may take many forms at differing levels of
intensity within behavioral medicine settings.
For example, the approach to assessments of
nicotine dependence in an emergency room is
likely to differ from the approach to assessments used in outpatient settings. Therefore,
the assessment should be tailored to the specific setting. Prior to beginning an assessment, the clinician should consider the
purpose for the assessment, the environment
where the assessment will take place, and the
form of intervention conducive to the setting.
Pretreatment Assessments
To provide adequate treatment, it is
essential that the clinician conduct the

1

most comprehensive evaluation possible. The
evaluation should include the assessment of
physiological, psychological, and social factors
that appear to Influence the patient's tobacco
use patterns (Ockene, Kristeller, & Donnelly,
1999). Pertinent information may be acquired
via a clinical interview, self-report measures, a
chart review, and corroboration from behavioral medicine staff. Ockene and colleagues
(1999) noted that, at the very least, an assessment of nicotine dependence starts with a
clinical interview. During this interview, physiological assessment questions should include
past quit attempts, withdrawal symptoms experienced during past quit attempts, and the
patient's perceived addiction to nicotine.
Questions within the social domain should
include the number of friends, family members,
and coworkers who use tobacco products; the
expected amount of social support or nonsupport; and the degree to whch the patient can be
assertive at rebuffing pressure from others to
smoke (Ockene et al., 1999) . Included withn
the psychological assessment should be questions related to emotional problems (e.g., stress,
depression), behavioral indexes (e.g., extent to
which person will go to have a cigarette), and
cognitive factors (e.g., self-efficacy beliefs about
quitting [Ockene et al., 19991). Ockene and
colleagues (1999) also noted that gathering
information about a patient's smoking history,
as well as having the patient self-monitor his or
her smoking behavior, can provide useful data
that may aid in treatment specificity. Finally,
health factors that may be a consequence of
chronic use patterns should also be assessed,
and patients who present with physical complaints (e.g., shortness of breath) should be
referred to a physician (Ockene et al., 1999).
Pretreatment assessment can be as brief as a
10-minuteclinical interview or as long as a 2%hour structured assessment. Again, the setting
and purpose of the assessment should dictate
the type of assessment administered. For a relatively brief assessment or for information that
will be incorporated within a larger assessment,
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there are a variety of standardized self-report
measures that can be used to assess level of
dependence, self-efficacy, readiness to quit, general reasons for use, and perceptions of what
tobacco products do for the person. For more
comprehensive interviews, several structured
and semistructured interviews are available,
including the Diagnostic Interview Schedule
(Malgady, Rogler, & Tryon, 1992) and the
Structured Clinical Interview for the DSM-IV
Axis I Disorders-Clinician Version (First,
Spitzer, Gibbon, & Williams, 1997).
Most self-report measures have adequate psychometric properties and have been used with a
variety of populations. Although a detailed
description of all tobacco-related measures available is beyond the scope of t h s chapter, the
following measures are recommended.
1. The Fagerstrom Test of Nicotine
Dependence (Heatherton, Kozlowski,
Frecker, & Fagerstrom, 1991): This is a 6item, self-report questionnaire designed to
assess various components of smoking
behavior, including an estimate of daily
intake, difficulty in refraining, and other
aspects related to the pattern of intake.
2. The Smoking Self-Efficacy Questionnaive
(Colletti, Supnick, & Payne, 1985): This is
a 17-item questionnaire designed to assess
respondents' beliefs about their ability to
control their urges to smoke in a variety of
situations.
3. The Smoking Consequences Questionnaire
(Brandon & Baker, 1991): The Smoking
Consequences Questionnaire (SCQ) is a 50item measure designed to assess expectations
associated with cigarette smoking. It has four
factors: negative consequences (e.g., health
risks), positive reinforcemendsensory satisfaction (e.g., taste, relaxation), negative reinforcemendnegative affect reduction (e.g.,
reduction of sadness and anxiety), and
appetitelweight control. The SCQ-Adult
(Copeland, Brandon, & Quinn, 1995) is an
extension of the SCQ for use with an older
population of dependent smokers.

4. The Contemplation Ladder (Biener &
Abrams, 1991): This is a measure of readiness to consider tobacco cessation. It is
designed to assess a tobacco user's position
on a continuum ranging from having no
thoughts of quitting to being engaged in
action to change one's tobacco use. The
ladder is consistent with Prochaska and
DiClemente's (1983) model, which states
that tobacco cessation is the culmination of
an extended process of behavior change. The
measure employs a picture of a ladder, where
each rung has an associated number that the
patient is instructed to circle representing
where he or she is in thinking about quitting.

Posttreatment Assessments
Posttreatment assessment allows the clinician to measure and adjust treatment efforts as
necessary. Issues that may arise include treatment compliance, sudden exacerbation of
clinical disorders (e.g., major depression),
severe tobacco withdrawal, intense and persistent urges to use nicotine, weight gain, brief
smoking lapses, and abstinence status. Many of
these issues can be assessed using clinical interviews. A supplementary self-report measure is
the Minnesota Nicotine Withdrawal Scale
(Hughes & Hatsukami, 1986), which assesses
withdrawal severity. This measure may be used
repeatedly to assess withdrawal across time.
For purposes of assessing treatment compliance, lapsing, and abstinence status, the clinician may assess tobacco use daily, weekly, or at
designated follow-up times. Self-reported lapses
and relapses in isolation or combined with biochemical verification have been used. A detailed
description of the utility of biochemical markers of tobacco and cessation as well as recommendations for their application in clinical
practice is beyond the scope of this chapter.
However, the Society for Research on Nicotine
and Tobacco Subcommittee on Biochemical
Verification (2002) recently published an
overview of this subject. In general, the committee noted that there are currently three
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biomarkers used to assess whether a person has
been abstinent from nicotine: thiocyanate
(SCN),cotinine, and expired carbon monoxide
(CO). SCN and cotinine are metabolites of
nicotine that indicate tobacco use over the
past week, and CO (as obtained via expired air)
indicates smoked tobacco use within the past
24 hours. The committee also noted that
the standard indication of tobacco use has
been cotinine levels above 15 nanograms per
milliliter, carbon monoxide levels above 8 to 10
parts per million, and SCN levels of 78 to 84
micromoles per liter. (For a more in-depth
review of biochemical verification recommendations, see Society for Research on Nicotine
and Tobacco Subcommittee on Biochemical
Verification, 2002.)

Treatment of Nicotine Dependence
The treatment of nicotine dependence
should be viewed as a multidisciplinary
stepped care approach. The stepped care
approach starts with the assessment of the
patient's motivation to quit and progresses to
the implementation of brief interventions. For
example, routine screening and brief counseling (less than 3 minutes) within emergency
rooms increase long-term abstinence rates
from 3 % (usualcare) to 8% to 11% (Bernstein
& Becker, 2002). If the patient is unmotivated
to quit, the clinician should incorporate
motivational enhancing techniques within the
brief intervention. Only after brief interventions are unsuccessful should the clinician
refer the patient to more intensive treatments.
As discussed in the next two subsections, all
recommendations for brief and intensive interventions are consistent with the clinical practice guidelines for treating nicotine dependence
(Fiore et al., 2000). It should be noted that
both brief and intensive interventions recommend the inclusion of pharmacological treatment. However, pharmacological agents
associated with treating nicotine dependence
are discussed in a separate subsection.

1

Brief Interventions
Brief interventions are designed to be used
in a variety of settings and should not take
more than 3 to 10 minutes. Brief interventions
include assessing tobacco use patterns and willingness to quit, advising the patient to make a
quit attempt, assisting the patient in quitting,
and scheduling follow-up sessions (Fiore et al.,
2000). Unfortunately, not all tobacco-using
patients are highly motivated to quit. In cases
where the patient is not so motivated, it is recommended that the clinician use an empathetic
therapeutic style that avoids arguments,
increases self-efficacy, and encourages adaptive
skills at quitting (Prochaska & Goldstein,
1991).Confrontational and punitive styles may
have the opposite effect by further decreasing
the patient's motivation to quit (Mller &
Rollnick, 2002).
Brief assistance that has been shown to
increase abstinence rates may be as simple as
providing the patient with self-help material
combined with recommending approved pharmacological treatment (Killen, Fortmann,
Newrnan, & Varady, 1990). Other brief techniques include (a)helping to identify upcoming
challenges, (b) processing helpful skills from
prior quit attempts, (c)reducing alcohol consumption during the first month of abstinence,
(d)encouraging others who use tobacco within
the same household to quit as well, (e)providing social support within the clinical environment, and (f) helping the patient to find another
supportive environment (Fiore et al., 2000).
The first follow-up session should be scheduled approximately 1 week after the quit date,
with the second scheduled 1 to 3 weeks later
(Fiore et al., 2000). During the follow-up, the
clinician should remain supportive, highlight
successes (no matter how small), and encourage problem solving. The patient may have a
tendency to overemphasize an aspect of the
quit attempt that is linked to failure (Shiffman
et al., 1996). If so, the clinician should try to
reframe the perceived failure as a learning
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experience and reengage the patient in problem solving (Fiore et al., 2000).
Intensive Treatments
It is recommended that intensive treatments be offered to all tobacco users because,
on average, such interventions are more effective than brief interventions (Fiore et al.,
2000). This recommendation, however,
might not be feasible. Thus, for each individual who wishes to quit, the clinician is
encouraged to use a stepped care approach
that starts brief and progressively increases in
intensity. The reason for this is that, under
certain circumstances, brief interventions can
be more effective than intensive interventions
(Smith et al., 2001), and brief interventions
are more practical in a variety of settings (e.g.,
primary care facilities).
Treatment Format
for
Intensive
Treatments. To qualify as an intensive treatment, there must be a minimum of four sessions lasting more than 10 minutes each (Fiore
et al., 2000). If feasible, group sessions of 8 to
10 people are recommended over individual
sessions because the group setting fosters social
support (Ockene et al., 1999). Sessions should
be scheduled on a weekly basis during the initial 4 weeks of treatment and then biweekly for
the next 4 weeks (Ockene et al., 1999).Finally,
posttreatment follow-ups should be scheduled
6 to 12 months after the quit date (Kozlowski,
Henningfield, & Brigham, 2001).
Treatment Components. Many of the psychosocial components used in tobacco cessation
treatment packages are cognitive-behavioral in
nature. The purpose of these components is to
break the association between smoking and
other Me activities and to increase the patient's
ability to cope during abstinence. As stated
earlier, pharmacological therapies are highly
recommended in conjunction with these
psychosocial interventions.

Before a patient attempts to quit, the patient
is encouraged to gather as much about his or
her smoking habit as possible. The patient is
asked to pay attention to specific triggers that
he or she believes will challenge the attempt
at quitting. Tobacco-related triggers include
situations, emotions, thoughts, and places
that evoke strong urges to use tobacco. Selfmonitoring smoking behavior prior to a quit
attempt often will help the patient to identify
tobacco-related triggers that are relevant to his
or her life. However, it is not atypical for many
other "unexpected7' triggers to arise once the
patient has achieved abstinence. Thus, it is
important to continue monitoring triggers long
after the quit date. It is also suggested that the
clinician provide the patient with education
regarding the withdrawal symptoms that he or
she may experience as well as the addictive
nature of tobacco because this information can
aid the patient in understanding the process of
addiction (Fiore et al., 2000; Kozlowski et al.,
2001). For example, skills training focused on
problem solving and symptom management
are helpful (Fiore et al., 2000). In addition,
there are several nonspecific treatment factors
that the clinician should provide during treatment. These treatment factors include discussing and eliciting positive expectancies,
being supportive and understanding, and providing a time line for the quit attempt (Fiore
et al., 2000; Kozlowski et al., 2001).
Once the patient quits, he or she may experience a variety of nicotine withdrawal symptoms that undermine quit attempts. It is
important for the clinician to assist the patient
in coping with these symptoms, particularly
during the first month of abstinence. The clinician should encourage the patient to use the
skills he or she learned during the pre-quit sessions. For example, encouraging the use of
relaxation techniques (e.g., removing oneself
from stressful situations, deep breathing)
provides an alternative means by which to
cope with stressful situations and negative
affect associated with tobacco withdrawal
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(Dziegielewski & Eater, 2000; Hatsukami &
Lando, 1999). The use of accessible substitutes, such as chewing gum, may also help the
patient to cope with withdrawal symptoms
(Cohen, Britt, Collins, al'Absi, & McChargue,
2001; Cohen, Britt, Collins, Stott, & Carter,
1999; Cohen, Collins, & Britt, 1997).In addition, encouraging the patient to avoid situations where tobacco use is likely to occur (e.g.,
bars, bowling alleys) as well as to engage in
healthy alternative behaviors (e.g., exercise)
may help to prolong abstinence (Dziegielewski
& Eater, 2000; Ockene et al., 1999).
Finally, working with the patient to develop
the requisite skills to elicit social support from
others outside of treatment is integral to successful tobacco cessation (Fiore et al., 2000).
One type of social support outside of therapy
that should be suggested is Nicotine Anonymous (NicA). These mutual-help groups provide social and emotional support for many
sufferers of addictive disorders through personal sharing on a weekly basis (Lichtenstein,
1999).It has been suggested that NicA may be
most effective for highly dependent smokers or
those who also abuse another substance (e.g.,
alcohol). At the very least, patients who do not
have a significant outside support system may
need more frequent contact from a clinician
to support them during their quit attempts
(Ockene et al., 1999).
Pharmacological Interventions
According to the Clinical Practice Guidelines
(Fiore et al., 2000), many first-line medications
exist for the treatment of nicotine dependence,
as do several second-he medications. First-he
medications have been established as efficacious
through clinical trials and have been approved
by the Food and Drug A h s t r a t i o n (FDA)
for use with nicotine dependence. First-line
medications include nicotine replacement products (e.g., gums, patches, nasal sprays, mhalers)
and buproprion-SR (sustainedrelease).With the
exception of nicotine gurn, these interventions

1

have been shown to approximately double
abstinence rates when compared with placebo
treatments.
Second-line treatments have also been
found to be efficacious, but the use of these
medications is limited due to the lack of FDA
approval as treatment for nicotine dependence as well as concerns about potential
side effects. Second-line treatments include
fluoxetine, clonidine, nortriptyline, and a
combination of nicotine replacement therapies. Mention of second-line therapies is limited to this paragraph because such therapies
are not viable treatment options at this time.
Thus, this subsection limits further discussion of pharmacology to first-line treatments.
Nicotine Replacement Therapy. Nicotine
replacement therapy (NRT) is intended to
break the conditioning of nicotine with environmental cues by making nicotine intake
independent of events in the environment
(Glover & Glover, 2001). Although NRT
provides lower doses of nicotine than do
other tobacco products, it can be used to
decrease the severity of withdrawal symptoms by providing a slow consistent dose of
nicotine through an alternate administration
route (Jarvis & Sutherland, 1998). NRT
comes in many different forms, including
gums, patches, nasal sprays, and inhalers.
Nicotine Polacrilex (gurn) was the first
NRT approved by the FDA (Jarvis &
Sutherland, 1998).The absorption rate is fairly
rapid, and peak nicotine levels are reached
within 20 to 30 minutes (Hatsukami &
Lando, 1999). Use is recommended for 3
months (Hatsukami & Lando, 1999).Although
nicotine gurn can be used on an as-needed basis
to control tobacco urges, a fixed schedule has
been shown to be more effective in dealing
with withdrawal symptoms (Ockene et al.,
1999). Nicotine gum is dispensed in 2- or
4-milligram doses, with the 4-milligram dose
recommended for heavily dependent smokers
(Fiore et al., 2000).
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The nicotine patch has a passive delivery
system. The absorption of nicotine is slower
than with the gum (Jarvis & Sutherland, 1998),
resulting in peak levels of nicotine 4 to 9 hours
after administration (Hatsumaki & Lando,
1999). The patch is available in either 24-hour
(Habitrol, Nicoderm, and Nicoderm CQ) or
16-hour doses (Nicotrol). Typically, 24-hour
patches have 21 or 22 milligrams of nicotine,
whereas patches designed for 16-hour use have
15 milligrams of nicotine (Hatsukami &
Lando, 1999; Ockene et al., 1999).
A nicotine nasal spray is available with a
prescription (Fiore et al., 2000) and
decreases craving within minutes of use due
to rapid absorption rates (Hatsukami &
Lando, 1999; Jarvis & Sutherland, 1998;
Ockene et al., 1999).Treatment is typically 6
to 8 weeks but can be extended to 3 months
in severe cases (Hatsukami & Lando, 1999;
Ockene et al., 1999). It is important to note
that the nasal spray may be more effective in
situations where instant relief from nicotine
craving is a priority (Hurt et al., 1998).
Finally, the nicotine inhaler dispenses 10 dligrarns of nicotine per Inhaler cartridge (Eissenberg, Stiker, & Henningfield, 1999; Hatsukami
& Lando, 1999).A unique feature of the inhaler
is that it provides oral and t a d e reinforcement
because it consists of a mouthpiece and a nicotine
cartridge as well as nicotine (Hatsukami &
Lando, 1999; Ockene et al., 1999).

Non-nicotine Therapies. Buproprion is
an antidepressant medication that has been
shown to aid in the management of nicotine
withdrawal symptoms (Johnston, Robinson,
Adams, Glassman, & Covey, 1999).Although
the mechanism of buproprion is not completely clear (Johnston et al., 1999), it is presumed to block neural reuptake of dopamine
and/or norepinephrine (Fiore et al., 2000).
Buproprion remains the only non-nicotine
medication used in tobacco cessation programs that is approved by the FDA (Fiore
et al., 2000; Johnston et al., 1999).

I f All Else Fails.

..

If all else fails, the clinician is advised to lower
tobacco use behavior when abstinence appears
to be initially unattainable (McChargue et al.,
2002a, 2002b) and/or pharmacological therapies are not suitable (Ockene et al., 1999).
Reducing tobacco use may be accomplished via
nicotine fading. Nicotine fading involves switching to a brand with lower nicotine levels as well
as gradually decreasing the quantity of tobacco
used (Ockene et al., 1999). For example, once
cigarette consumption has been decreased to 5
to 10 cigarettes per day and has been stabilized
at this level, a quit date should be reestablished
(Ockene et al., 1999).

CONCLUSIONS
Chronic use of tobacco products has been
linked to a number of serious health problems
that affect many people throughout the
world. It appears that nicotine dependence
develops via the interaction between neurobiological substrates and cognitive, behavioral,
and emotional domains. Although there are a
variety of factors that contribute to the development of nicotine dependence, once people
are dependent, it is clear that they have
extreme difficulty in quitting. For the most
part, treatment of nicotine dependence takes
a stepped care approach, which begins with
brief interventions and progresses to more
intensive interventions. The goal of this chapter was to increase knowledge about nicotine
dependence and to provide guidance on intervention strategies for treating individuals with
nicotine dependence. Given the pervasiveness
of tobacco use disorders among various
patient populations and the health consequences associated with these disorders, treatment of nicotine dependence is one area in
which clinical health psychologists can have a
positive impact on their patients' overall
health status.
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CASE STUDY
This case study illustrates an intensive smoking treatment. The client, "Betty," was
a 67-year-old Caucasian female who was referred by her primary care physician
for individual smoking treatment. Betty presented with complaints of having "no
control" over her smoking behavior but having a strong desire to quit smoking.
She also reported that her health was "failing" and that her physician would not
perform "a necessary medical procedure" unless she quit. Specifically, Betty noted
that she suffered from numerous medical problems, including chronic bronchitis,
asthma, and emphysema. Medical concerns had reduced her independence by
causing her to rely on a motorized scooter for community mobility. Betty reported
that she lived in an apartment by herself and noted that she had very little local
social support. She did indicate, however, that she had several relatives who lived
"out of state" with whom she talked via phone on a weekly basis.
During Betty's intake session, she was asked to exhale into a CO monitor and to
complete the Fagerstrom Test of Nicotine Dependence. Results revealed a CO reading of 48 parts per million (indicatingheavy smoking rates) and a test score of 9 (indicating a high level of nicotine dependence). In addition to these measures, a detailed
account of her smoking history and quit attempts was obtained via clinical interview.
In sum, Betty reported smoking her first cigarette at the age of 12 years and progressing to daily cigarette smoking by the age of 14 years. She noted that when she
was smoking at her heaviest rate, she smoked two packs (40 cigarettes) per day, but
she was currently smoking 25 cigarettes per day. Betty reported that she had tried
unsuccessfully to quit smoking many times in her life, noting that she could recall four
occasions when she made "serious attempts" to quit by using group smoking cessation programs, using nicotine replacement patches, and stopping "cold turkey." Betty
made it clear to the therapist that she did not want to use nicotine replacement
patches this time because she had "vivid disturbing dreams" the last time she had
used them. She noted that her previous quit attempts resulted in temporary cessation,
with her longest period of abstinence being a little more than 1% years. She also
noted, on a scale of 1 to 10, that she had a strong desire to quit smoking (10110),that
it was very important that she quit smoking (10110),but that she was only somewhat
confident in her ability to quit (5110).
Betty agreed to attend weekly sessions for the next 8 weeks. Betty and the
therapist collaboratively planned to reduce her nicotine intake and to have her
learn more about her smoking behavior (e.g., when she smoked, where she
smoked, why she smoked) during the first 4 weeks of treatment. A quit date was
set for Week 5, and during Weeks 6 to 8 it was decided that the focus of treatment
would be on issues related to relapse prevention. Betty left the intake session with
two "homework" assignments, namely (a)to attempt to reduce smoking intake by
10% during the week and (b)to keep a written record of her smoking behavior.
Specifically, each time she was about to smoke a cigarette, Betty was asked to write
down the time of day, any emotions she was feeling at the time, and the situational
circumstances that occurred just prior to her smoking.
-
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Betty presented for her second session on time and indicated that she
had reduced her smoking intake successfully and kept accurate records of her
smoking behavior. She was eager to report that by the end of the week, she was
able to reduce her smoking to 10 cigarettes per day (a far greater reduction than
the agreed-on 10%). She also noted that she wanted to smoke more frequently
than she actually did; however, she "got sick" of writing down all of the requested
information before each cigarette. She noted that tracking her smoking behavior
allowed her to cut out many cigarettes that she did not "really need." She also
indicated that in reducing her smoking intake, she learned that the "cravings" she
had to smoke throughout the day would not "last forever" and in fact passed
rather quickly, usually within 10 to 15 minutes. After praising Betty on the
progress she had made during the past week, the therapist reviewed the "smoking
record sheets'' that Betty had completed in an attempt to identify commonalities in
her smoking behavior. Examination of the smoking record sheets revealed that
Betty smoked most often after eating meals and during times of perceived stress.
In an attempt to aid Betty during these difficult times, urge control strategies
were discussed.
One of the keys to success in smoking cessation is learning how to get through
urges or cravings to smoke. Given that Betty had already learned how to get
through some of her urges to smoke, the therapist enlisted Betty's help to get a
sense of what worked for her during the past week. Betty noted that if she just
waited long enough, her urge to smoke would go away (although she was quick to
point out that the urges would return). Building on Betty's success, the therapist
noted that delaying smoking might not work in all situations and taught Betty a
number of other urge control strategies that might prove to be useful in situations
where delaying smoking was too difficult. The therapist outlined five basic
strategies that Betty could pull from her "tool box" when faced with difficult urges:
(a)delaying smoking, (b)escaping from situations or events that may contribute to
the urge, (c) avoiding situations where the temptation to smoke may be too great,
(d) distracting herself by thinking about or doing other things that she enjoys
doing, and (e) substituting something else for a cigarette such as sugarless gum,
candy, or sunflower seeds. (All of these strategies can be remembered by the simple
yet appropriate acronym of DEADS.) The therapist encouraged Betty to continue
doing what worked for her the previous week and to try some of the other strategies that were taught when the urge to smoke surfaced. For "homework," Betty
was again encouraged to reduce her smoking by 10%. The therapist also encouraged Betty to pick a "smoking place" in her home where she usually did not smoke
and did not engage in other activities such as talking on the phone, socializing,
eating, watching television, and reading mail. It was suggested that she smoke only
in this place, with the idea being that she would not associate smoking in this place
with any other kind of activity. Also, it would mean that she would have to stop
what she was doing so as to smoke a cigarette.
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During the third and fourth weeks of treatment, Betty was able to
reduce her smoking to 4 cigarettes per day using the strategies discussed earlier.
In anticipation of the Week 5 quit date, most of the fourth session was centered
on preparing Betty for her quit attempt. She was instructed to have her final
cigarette no later than before she went to bed on the night before she was to attend
her fifth session. She was also encouraged to "seek out and destroy" all of the
cigarettes that remained in her apartment that evening so as to be sure that there
would not be any cigarettes readily available to her when she woke up the next
morning. She was also educated about what types of withdrawal symptoms she
might expect (e.g., depressed mood, irritability, anxiety) so that they would not
catch her "off guard." In addition, detailed plans were made outlining how
she would deal with her cravings to smoke so that she had a "plan of attack" if a
craving surfaced. She was also encouraged to start thinking about how to reward
herself once she quit.
During the fifth session, Betty was not as animated as she had been during the
previous 4 weeks of treatment. She reported that she had not smoked a cigarette
since before she went to bed the previous evening; however, she noted that she
"really wanted one." The therapist reinforced Betty for all of her hard work and
reminded her that her cravings would pass and that the intensity and frequency
of the cravings would dissipate over time. The remainder of the session was spent
discussing the health benefits that she could expect over the next several weeks
(e.g., decrease in coughing and sinus congestion, increase in overall energy level).
Finally, Betty was informed that she might "slip" and smoke a cigarette during
the course of the next week. She was told that this is "normal" and that if it happens, she should look at it as just a "slip," not a "total relapse." She was encouraged to get back to being "smoke free" after the slip rather than to give herself
permission to smoke as many cigarettes as she wanted and view her efforts as a
failure.
Sessions 6 to 8 began with Betty exhaling into the CO monitor to show her that
her CO levels were decreasing, thereby increasing the amount of oxygen that was
circulating throughout her body. Her readings were 11, 8, and 7, respectively. In
addition, these sessions centered on ways in which Betty could prevent relapse. She
had done exceptionally well and did not experience a slip during these 3 weeks.
Betty and the therapist worked on anticipating difficult situations and planned
ahead as to how she would cope with these situations if and when they arose. Betty
was particularly concerned about what she would do in stressful situations that
were bound to arise in the future. It was discussed how she could take a "time out,"
removing herself from the situation, taking deep breaths, andlor thinking of something fun she had recently done rather than smoking. At the end of Session 8, Betty
was commended for her hard work, given information about local support groups
(in case she desired additional help), and was scheduled for three "booster
sessions" 1, 3, and 6 months later.
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At 1-month follow-up, Betty reported that she had one slip during the holidays
as she was caught off guard by her "emotions." She noted that she recognized what
she was doing and immediately put out the cigarette and did not allow herself to
smoke again. She noted that she repeatedly reminded herself of her hard work and
told herself that she refused to "go back to Square One." She also noted that this
slip was a "reality check" and reminded her that she should not get overconfident
about her progress and that she had to continue to work on her addiction to nicotine. Betty admitted that she "would be lying" if she said she did not want a
cigarette. But she added that the cravings were not occurring as often and that they
were not as severe when they did occur. Betty was praised by the therapist and was
encouraged to "keep her guard up." At the 3- and 6-month follow-ups, Betty
reported that she had not slipped again and that her energy levels were up. At the
6-month follow-up, she reported that it looked as though her physician was
considering performing the medical procedure she needed.
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